A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center phase II clinical study consisting of two parts:
Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer.
Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.